September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Comparing of Bevacizumab and Combination Low-Dose Bevacizumab-Triamcinolone in Central Retinal Vein Occlusion
Author Affiliations & Notes
  • Seong-Jae Kim
    Gyeongsang National University Hospital, Jinju, Korea (the Republic of)
  • Inyoung Chung
    Gyeongsang National University Hospital, Jinju, Korea (the Republic of)
  • Hyun Woong Kim
    Busan Paik Hospital, Busan, Korea (the Republic of)
  • Seongwook Seo
    Gyeongsang National University Hospital, Jinju, Korea (the Republic of)
  • Jong Moon Park
    Gyeongsang National University Hospital, Jinju, Korea (the Republic of)
  • Footnotes
    Commercial Relationships   Seong-Jae Kim, None; Inyoung Chung, None; Hyun Woong Kim, None; Seongwook Seo, None; Jong Moon Park, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 5334. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Seong-Jae Kim, Inyoung Chung, Hyun Woong Kim, Seongwook Seo, Jong Moon Park; Comparing of Bevacizumab and Combination Low-Dose Bevacizumab-Triamcinolone in Central Retinal Vein Occlusion. Invest. Ophthalmol. Vis. Sci. 2016;57(12):5334.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To report the effects and intraocular pressure results of intravitreal bevacizumab alone injection compared with intravitreal low-dose bevacizumab combined with low-dose triamcinolone injection in patients with central retinal vein occlusion.

Methods : In total, 40 eyes of 40 patients diagnosed with central retinal vein occlusion were evaluated. Of these, 20 eyes of 20 patients were injected with intravitreal bevacizumab (1.25 mg/0.05 mL) and 20 eyes of 20 patients were injected with low-dose bevacizumab (0.625 mg/0.025 mL) combined with low-dose triamcinolone (1 mg/0.025 mL). The best corrected visual acuity (BCVA), central macular thickness, and intraocular pressure of treated eyes were measured before injection and at 1 month, 2 months, and 3 months after injection.

Results : In both the intravitreal bevacizumab and the low-dose bevacizumab combined with low-dose triamcinolone groups, central macular thickness decreased significantly at 1 month, 2 months, and 3 months after injection (p < 0.05). In addition, in both groups, neither intraocular pressure (IOP) nor BCVA decreased significantly at 1 month, 2 months, or 3 months after injection (p > 0.05). The BCVA, IOP, and central macular thickness (CMT) at 1 month, 2 months, and 3 months after injection showed no significant differences between the intravitreal bevacizumab group and the low-dose bevacizumab combined with low-dose triamcinolone group (p > 0.05).

Conclusions : The the CMT of both groups decreased significantly, and BCVA of both groups increased significantly in patients with central retinal vein occlusion. The injection of low-dose intravitreal bevacizumab combined with low-dose intravitreal triamcinolone may be useful for the treatment of central retinal vein occlusion. injection (p > 0.05). The BCVA, IOP, and central macular thickness (CMT) at 1 month, 2 months, and 3 months after injection showed no significant differences between the intravitreal bevacizumab group and the low-dose bevacizumab combined with low-dose triamcinolone group (p > 0.05).

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×